180 related articles for article (PubMed ID: 38175444)
61. [Clinical value of minimal residual disease detection by flow cytometry in childhood B-cell acute lymphoblastic leukemia].
Chang L; Zhang G; Shi H; Ye L; Jiang YM
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Dec; 16(12):1245-9. PubMed ID: 25523574
[TBL] [Abstract][Full Text] [Related]
62. Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL.
Das N; Gupta R; Gupta SK; Bakhshi S; Seth R; Kumar C; Rai S; Singh S; Prajapati VK; Gogia A; Sahoo RK; Sharma A; Kumar L
Ann Hematol; 2021 Oct; 100(10):2487-2500. PubMed ID: 34236495
[TBL] [Abstract][Full Text] [Related]
63. [Clinical significance of minimal residual disease in patients with Ph-negative precursor B-acute lymphoblastic leukemia].
Liu KQ; Wei H; Lin D; Wang Y; Zhou CL; Liu BC; Li XL; Zhao Y; Li HJ; Wang CW; Li QH; Li BF; Gong YT; Liu XY; Gong YC; Mi JX; Wang J
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):724-728. PubMed ID: 30369181
[No Abstract] [Full Text] [Related]
64. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
65. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
[TBL] [Abstract][Full Text] [Related]
66. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
67. Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Girase K; Verma S; Arolkar G; Dasgupta N; Narula G; Shetty D; Dhamne C; Moulik NR; Rajpal S; Patkar NV; Banavali S; Gujral S; Subramanian PG; Tembhare PR
Br J Haematol; 2022 Jan; 196(2):374-379. PubMed ID: 34476808
[TBL] [Abstract][Full Text] [Related]
68. Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.
Gao Q; Liu Y; Aypar U; Baik J; Londono D; Sun X; Zhang J; Zhang Y; Roshal M
Cytometry B Clin Cytom; 2023 Jul; 104(4):279-293. PubMed ID: 36999235
[TBL] [Abstract][Full Text] [Related]
69. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
[TBL] [Abstract][Full Text] [Related]
70. Monitoring of minimal residual disease in acute leukemia by multiparametric flow cytometry.
Kusenda J; Fajtova M; Kovarikova A
Neoplasma; 2014; 61(2):119-27. PubMed ID: 24299307
[TBL] [Abstract][Full Text] [Related]
71. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
72. Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia.
Akabane H; Logan A
Clin Adv Hematol Oncol; 2020 Jul; 18(7):413-422. PubMed ID: 32903253
[TBL] [Abstract][Full Text] [Related]
73. B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis.
Shaver AC; Seegmiller AC
Clin Lab Med; 2017 Dec; 37(4):771-785. PubMed ID: 29128068
[TBL] [Abstract][Full Text] [Related]
74. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.
Gökbuget N; Zugmaier G; Dombret H; Stein A; Bonifacio M; Graux C; Faul C; Brüggemann M; Taylor K; Mergen N; Reichle A; Horst HA; Havelange V; Topp MS; Bargou RC
Leuk Lymphoma; 2020 Nov; 61(11):2665-2673. PubMed ID: 32619115
[TBL] [Abstract][Full Text] [Related]
75. A 19-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia.
Fokken H; Waclawski J; Kattre N; Kloos A; Müller S; Ettinger M; Kacprowski T; Heuser M; Maetzig T; Schwarzer A
Cytometry A; 2024 Mar; 105(3):181-195. PubMed ID: 37984809
[TBL] [Abstract][Full Text] [Related]
76. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
77. [The limited possibility of using a simplified approach to detect minimal residual disease by the flow cytometry technique in children with precursor B-lineage acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia T; Tsaur GA; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
Klin Lab Diagn; 2011 Mar; (3):25-9. PubMed ID: 21574456
[TBL] [Abstract][Full Text] [Related]
78. Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation.
Zhao X; Zhao X; Chen H; Qin Y; Xu L; Zhang X; Liu K; Huang X; Chang YJ
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1936-1943. PubMed ID: 29572111
[TBL] [Abstract][Full Text] [Related]
79. Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia.
Choi JK; Mead PE
Clin Lab Med; 2023 Mar; 43(1):115-125. PubMed ID: 36764804
[TBL] [Abstract][Full Text] [Related]
80. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
Verbeek MWC; Buracchi C; Laqua A; Nierkens S; Sedek L; Flores-Montero J; Hofmans M; Sobral de Costa E; Nováková M; Mejstrikova E; Barrena S; Kohlscheen S; Szczepanowski M; Kulis J; Oliveira E; Jugooa R; de Jong AX; Szczepanski T; Philippé J; van Dongen JJM; Orfao A; Brüggemann M; Gaipa G; van der Velden VHJ
Br J Haematol; 2022 Apr; 197(1):76-81. PubMed ID: 34881427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
